Re-Programming Autoreactive T Cells Into T-Regulatory Type 1 Cells for the Treatment of Autoimmunity

Re-Programming Autoreactive T Cells Into T-Regulatory Type 1 Cells for the Treatment of Autoimmunity

Systemic delivery of peptide-major histocompatibility complex (pMHC) class II-based nanomedicines can re-program cognate autoantigen-experienced CD4+ T cells into disease-suppressing T-regulatory type 1 (TR1)-like cells. In turn, these TR1-like cells trigger the formation of complex regulatory cell...

Full description

Bibliographic Details
Main Authors: Patricia Solé, Pere Santamaria
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Immunology
Subjects:
T-regulatory type 1 (TR1) cells
peptide-MHC class II-coated nanoparticles
T-cell reprogramming
interleukin 10 (IL10)
autoimmune disease
therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.684240/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.684240/full

Similar Items